Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 41.3% in August

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 104,202 shares, a decrease of 41.3% from the July 30th total of 177,544 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average trading volume of 316,969 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Enlivex Therapeutics

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at $33,000. Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics during the 3rd quarter worth about $57,000. Invesco Ltd. purchased a new stake in Enlivex Therapeutics during the 4th quarter worth about $43,000. XTX Topco Ltd raised its stake in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares in the last quarter. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Trading Down 2.4%

Shares of ENLV stock traded down $0.03 during trading hours on Wednesday, hitting $1.25. The company’s stock had a trading volume of 134,075 shares, compared to its average volume of 102,969. The business has a fifty day moving average of $4.09 and a 200-day moving average of $10.18. Enlivex Therapeutics has a twelve month low of $1.15 and a twelve month high of $27.15. The stock has a market cap of $21.84 million, a price-to-earnings ratio of -0.15 and a beta of 1.42.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ENLV shares. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Finally, Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enlivex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.